Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Steven Leach
 -- 2294 2023-12-04 04:22:11 |
2 layout
Jessie Wu
 Meta information modification 2294 2023-12-04 06:10:00 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Wong, P.Y.; Yip, C.; Lemberg, D.A.; Day, A.S.; Leach, S.T. Characterising a Pathogenic Microbiome. Encyclopedia. Available online: https://encyclopedia.pub/entry/52297 (accessed on 27 July 2024).
Wong PY, Yip C, Lemberg DA, Day AS, Leach ST. Characterising a Pathogenic Microbiome. Encyclopedia. Available at: https://encyclopedia.pub/entry/52297. Accessed July 27, 2024.
Wong, Pui Yin, Carmen Yip, Daniel A. Lemberg, Andrew S. Day, Steven T. Leach. "Characterising a Pathogenic Microbiome" Encyclopedia, https://encyclopedia.pub/entry/52297 (accessed July 27, 2024).
Wong, P.Y., Yip, C., Lemberg, D.A., Day, A.S., & Leach, S.T. (2023, December 04). Characterising a Pathogenic Microbiome. In Encyclopedia. https://encyclopedia.pub/entry/52297
Wong, Pui Yin, et al. "Characterising a Pathogenic Microbiome." Encyclopedia. Web. 04 December, 2023.
Characterising a Pathogenic Microbiome
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm12227184

The process of microbiome development arguably begins before birth. Vertical transmission of bacteria from the mother to the infant is a keystone event in microbiome development. Subsequent to birth, the developing microbiome is vulnerable to influence from a wide range of factors. Additionally, the microbiome can influence the health and development of the host infant. This intricate interaction of the gastrointestinal microbiome and the host has been described as both symbiotic and dysbiotic. Defining these terms, a symbiotic microbiome is where the microbiome and host provide mutual benefit to each other. A pathogenic microbiome, or more precisely a gastrointestinal microbiome associated with disease, is increasing described as dysbiotic. 

dysbiosis microbiome infant childhood inflammatory disease

1. Dysbiosis

Deviation from a healthy microbiome is commonly described as dysbiosis [1]. Dysbiosis can be defined as an altered composition and diversity of the gut microbiome that is associated with ill-health and disease. More specifically, dysbiosis disrupts immune suppressing host–microbe interactions and promotes inflammation, pathogenicity, and disease. With prolonged dysbiosis, there is an overgrowth of pathogenic bacteria with virulence factors, decreased regulatory or beneficial bacteria, and loss of bacterial diversity [2], which leads to dysfunction in the immune response and the promotion of a proinflammatory environment [1][3].
With dysbiosis, the homeostatic bacterial metabolic functions are altered, which can lead to a defective mucosal barrier [3]. It has been proposed that an increase in mucolytic bacteria such as Ruminococcus gnavus [4] and reduction in antimicrobial peptides such as Paneth cell-derived alpha-defensins, compromise the integrity of the mucosal barrier and are contributing factors in conditions such as inflammatory bowel disease (IBD) [5]. These factors also increase the risk of microbial overgrowth and bacterial translocation, which can further activate the host immune response via modulation of proinflammatory signalling pathways [3].
Pathobionts, or bacteria that display pathogenic properties opportunistically, can express virulence factors [6]. One example is the release of endotoxins, which act as ligands that bind cell surface receptors on innate immune cells, initiating cell activation [7]. Activated immune cells then upregulate their expression of pattern recognition receptors, which recognise microbe, pathogen, and danger-associated molecular patterns released by microbes and inflammatory cells [1]. In conjunction with reduced immune suppression from commensal bacteria, pathobionts lead to dysregulation in T cell differentiation that promotes the release of proinflammatory cytokines [8]. The resulting inflammatory environment induces host tissue damage and predisposes to diseases including IBD, irritable bowel syndrome, colorectal cancer, and extraintestinal diseases such as obesity and diabetes [9][10][11]. Table 1 outlines examples of several pathobionts and their molecular mediators suggested to contribute to disease.
Table 1. Examples of pathobionts and their molecular mediators associated with disease.
Pathobionts Molecular Mediators Association with Disease
Escherichia coli Produce lipopolysaccharides (LPS), activating toll-like receptor (TLR) signalling and inflammatory cascades including release of interleukin-8 (IL-8) in colonic and intestinal epithelial cells [12]
Adherent invasive E. coli strains express cell adhesion molecules to facilitate colonisation in the intestinal mucosa, with virulence factors including type 1 pili and long polar fimbriae expression [13]
Promote cancer through activation of T-helper (Th)-17 cells, direct DNA damage, and induction of cholesterol synthesis [9]		 IBD
Type 2 Diabetes
Fatty liver disease
Colorectal cancer [14]
Clostridioides difficile Mucolytic enzymes such as cell surface protein Cwp84 which degrades the colonic mucosa and surface layer protein A (SlpA) which activates TLR4-dependent responses and aids colonisation
Clostridial toxins A and B (TcdA and TcdB) stimulate inflammatory chemokine and cytokine production, neutrophil influx, disruption of tight junctions, fluid secretion, and epithelial cell death [15]		 Pseudomembranous colitis
Enterotoxigenic Bacteroides fragilis (ETBF) Induces colonic signal transducer and activator of transcription-3 (Stat3) activation; colitis characterised by Th-17 response [16]
Induces spermine oxidase (SMO) resulting in increased reactive oxygen species (ROS) and DNA damage [17]		 Colorectal cancer
Helicobacter pylori Induces SMO leading to ROS production and DNA damage [17]
Cytotoxins VacA and CagA injected into host cell, activating oncogenic signal transduction pathways [9]
Changes in microbial flora from atrophic gastritis to intestinal metaplasia and dysplasia, leading to increased carcinogenic potential of bacterial strains and formation of carcinogenic N-nitroso compounds [18]		 Peptic ulcer disease, gastritis, gastric cancer
Enterococcus faecalis Inoculation of E. faecium strain ATCC 19434 in IL-10 depleted mice increased expression of inflammatory cytokines tumour necrosis factor, IL-1b, IL-6, IL-17a, and IL-12b [19] Ulcerative colitis
Proteus mirabilis P. mirabilis strains present in mice showed bacterial adherence, invasion, and increased production of pro-inflammatory cytokines IL-18 and IL-1α and cell necrosis
Induce pro-inflammatory pathways including nucleotide-binding oligomerisation domain (NOD)-like receptor signalling, Jak-STAT signalling, and MAPK signalling [20]		 Crohn’s disease
A number of indices have been proposed to measure and assess dysbiosis. These include large-scale bacterial marker profiling, relevant taxa-based methods, neighborhood classification, random forest prediction, and combined alpha-beta diversity [21][22][23]. However, the most common method to measure and assess dysbiosis is to measure diversity. Alpha diversity describes the amount of unique taxa (richness) and their distribution (evenness) within a microbial community. Beta diversity is used to assess differences in microbial community composition between individuals, such as between those with a disease state and healthy controls [21]. Overall, multiple indices suggest that a single measure fails to address the broad concepts within dysbiosis. Furthermore, these measures cannot distinguish whether dysbiosis is a cause or consequence of disease [24][25][26].

2. The Pathogenic Microbiome in Inflammatory Disease

A prominent inflammatory disease is IBD, which is a chronic inflammatory condition of the GI tract with episodes of relapse and remission [3]; it is predominantly classified into Crohn’s disease (CD) and ulcerative colitis (UC). CD can affect the entire GI tract with transmural involvement, while UC is characterised by a more superficial inflammation that is confined to the large intestine [27]. The prevalence of IBD has increased in Western countries, with a rising incidence in newly industrialised countries [28]. Up to 25% of patients present with symptoms during adolescence and young adulthood [29]. Children typically develop a more aggressive disease course [30], with detrimental effects on growth, development, and psychosocial wellbeing [28]. The pathogenesis of IBD is multifactorial, with interactions between host genetics, a dysregulated immune response, environmental exposures, and importantly, changes in the gut microbiome contributing to disease [3].
Different factors can alter the intestinal microbiome [31]. Diet, including feeding from birth, is a notable environmental factor that profoundly impacts microbiome composition. For instance, the microbiome of formula-fed infants is characterised by decreased diversity and bacterial richness, which is associated with inflammation [32]. Bolte et al. [33] also found that the Westernised diet, consisting of lower dietary fibre and higher consumption of animal fat, salt, and sugar [34], induces microbiome characteristics that correspond with intestinal inflammation, while plant-based diets were associated with SCFA-producers and lower abundance of pathogenic bacteria. These observations are also supported by Zheng et al. [35] who found correlations between the abundance of several bacterial species and a proinflammatory diet (defined as a diet containing dietary components known to be associated with inflammation). Two further studies have also found associations between IBD and the consumption of high-sugar foods [36][37].
Antibiotic exposure is an additional environmental factor that can induce a loss of health-promoting bacteria and reduced expression of antibacterial agents and immunoglobulins, resulting in the potential to increase susceptibility to infections [38]. Antibiotic use corresponds with an increase in inflammatory cytokines, alteration of insulin sensitivity, and modulation of the metabolism of SCFAs and bile acids [39]. A cohort study conducted by Hviid et al. [40] reported associations between antibiotic exposure during childhood and the development of IBD. Additionally, maternal antibiotic use during pregnancy and infantile antibiotic exposure increases the risk of very early onset IBD [26][41]. Antibiotic use in infants small for gestational age showed an increase in pathogenic species associated with a ‘dysbiotic’ microbiome [42][43]. In addition to antibiotic exposure in premature and small-for-gestational-age infants, other early life factors including Caesarean section delivery and formula feeding increase the risks of asthma, atopy, obesity, type 2 diabetes mellitus, necrotising enterocolitis, and sepsis [42][44][45][46][47][48][49][50].
Significant efforts have been directed at identifying the pathogenic microbiome characteristics of inflammatory disease and in particular IBD [51][52][53][54][55][56][57]. Most studies have identified a decrease in alpha diversity in individuals with CD compared to UC and healthy controls [52][54][55][56][57]. However, a systematic review by Pittayanon et al. [51] reported that the most common findings of a decrease in the species Faecalibacterium prausnitzii and an increase in Enterobacteriaceae, were characteristic of IBD. F. prausnitzii is a SCFA-producer with metabolomic studies showing reduced SCFAs in the GI tract of individuals with IBD [53].
Furthermore, SCFA-producers, such as F. prausnitzii and Roseburia hominis, reduce proinflammatory cytokines including interleukin (IL)-12 and interferon-gamma and increase anti-inflammatory cytokines including IL-10 [24], implying that reduced SCFA-producing bacteria may be a marker of the pathogenic microbiome. Enterobacteriaceae, such as E. coli and Shigella, are facultative anaerobes and are enriched in inflammation at the expense of obligate anaerobes, which may be due to oxidative stress during inflammation [22]. These bacteria produce lipopolysaccharides (LPS), a pathogen-associated molecular pattern that activates Toll-like receptor signalling and a consequent inflammatory cascade [12].
As an illustration of this, a study of GF mice found that the mice developed colitis when colonised by a highly endotoxic intestinal microbiome containing a high proportion of Enterobacteriaceae (including E. coli) and a low proportion of Bacteroidetes [58]. Pathogenic strains of E. coli, including adherent-invasive E. coli (AIEC), have also been reported to be associated with IBD [59]. AIEC can induce the expression of cell adhesion molecules and they possess virulence factors such as type 1 pili and long polar fimbriae, which can facilitate colonisation in the intestinal mucosa [13]. Although E. coli can be considered part of the normal GI microbiome, a pathogenic and disproportionate abundance of E. coli may also constitute a pathogenic microbiome.
A caveat is that most studies on the microbiome in IBD are cross-sectional or longitudinal over short periods such as one year. Therefore, it is difficult to determine whether the previously described microbiome characteristics are a cause or consequence of disease. Furthermore, the GI microbiome is not homogenous, with reported differences in the microbiome between faecal and biopsy samples [12]. In addition, IBD is a heterogenous disease and findings for individuals with mild disease may not be valid for individuals with moderate or severe disease [52].

3. The Pediatric Pathogenic Microbiome

A further consideration of the contribution of the microbiome to disease is age. As previously described, in early childhood the gut microbiome is generally considered to be similar in composition and diversity to that of adults [60]. However, some studies report differences in the microbial composition between younger children and adolescents, suggesting continual development of the microbiome with age [32][61][62]. Furthermore, studies of the microbiome of treatment-naïve children with IBD suggests that the microbiome is characterised by reduced abundances of certain bacterial species rather than an increase in pathogens [22][63][64]. This highlights that in children at least, the pathogenic microbiome may be characterised by a loss of physiological functions.
However, a systematic review of gut microbiome profiles of children with IBD, commonly reported decreased alpha diversity and beta diversity that differed from healthy controls [28]. Overall, the IBD microbiome in children showed increased Enterococcus and decreased Anaerostipes, Blautia, Coprococcus, Faecalibacterium, Roseburia, Ruminococcus, and Lachnospira [28]. As these findings are also similar to adult IBD, it was proposed that the conditions for adult-onset IBD may be established during childhood [28].
Associations between the microbiome and disease severity or outcomes have also been investigated. Olbjørn et al. [62] reported that patients with higher abundance of Proteobacteria were more likely to require aggressive treatment and surgery. Proteobacteria abundance also correlated with increased CD complications and an absence of mucosal healing [62]. It is of interest that E. coli is classified within the Proteobacteria phylum. However, no firm conclusions can be reached whether specific species within the Proteobacteria phylum, or whether a common characteristic shared by the phylum, is contributing to these findings [62].
Paediatric studies have also investigated associations between dysbiosis, disease activity and treatment response [23][28][62][63][64][65][66]. Overall, dysbiosis positively correlated with disease activity in children [28][66]. Of interest was that hydrogen sulfide (H2S)-producers, such as Fusobacterium, Prevotella, and Streptococcus, were increased with inflammation [28]. H2S can damage the intestinal epithelium and influence the microbiome, mucous, and biofilm interactions [28]. Therefore, H2S and H2S-producers should also be a consideration of the pathogenic microbiome.
Contrary to these findings is that de Meij et al. [64] found no association between microbiome profile and disease activity. Further studies have also reported that with treatment, bacterial profiles and dysbiosis remain [23][62]. However, these studies also highlighted that consideration should also be given to the type of treatment, and/or treatment success. Kolho et al. [65] reported that microbial composition and diversity increased in treatment responders, following six weeks of anti-tumour necrosis factor-α therapy. Specific changes associated with treatment response have also been identified with Eubacterium and Bifidobacterium associated with a favorable response to medication [65][67]. A further study of the oral microbiome also found associations between bacterial species and treatment response [68]. These findings support the idea that analysis of the microbiome may potentially assist in the assessment and management of IBD.
A further factor that requires consideration is that the microbiome itself may be contributing to dysbiosis. The essence of this hypothesis is that symbiont bacteria can potentially evolve into pathobiont bacteria under specific selective pressures [69], which is feasible due to the rapid reproductive cycle of prokaryotes. The potential for a rapidly evolving microbiome is illustrated by the example that there are approximately the same number of reproductive events occurring in the average human microbiome in 5 days, as in the entire human population over the last 66 million years [70].
In recognition of these factors, the concept of microbiome engineering has emerged recently [71]. These include primary preventive strategies such as education on the consequences of Caesarean section delivery, conservative use of antibiotics during pregnancy, administration of antibiotics after cord clamping to limit foetal exposure and the adoption of the WHO Baby Friendly Hospital Initiative [72]. Current secondary prevention methods include pre- and probiotics supplementation of the mother during pregnancy and the neonate after birth, faecal microbiome transplantation and phage therapy [69]. At present, the literature surrounding neonatal microbiome engineering is relatively unexplored but poses a pivotal opportunity to promote robust microbiome development and prevent long-term pathologies associated with a disrupted microbiome.

References

  1. Santana, P.T.; Rosas, S.L.B.; Ribeiro, B.E.; Marinho, Y.; de Souza, H.S.P. Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets. Int. J. Mol. Sci. 2022, 23, 3464.
  2. Eun, C.S.; Mishima, Y.; Wohlgemuth, S.; Liu, B.; Bower, M.; Carroll, I.M.; Sartor, R.B. Induction of bacterial antigen-specific colitis by a simplified human microbiota consortium in gnotobiotic interleukin-10-/- mice. Infect. Immun. 2014, 82, 2239–2246.
  3. Talapko, J.; Vcev, A.; Mestrovic, T.; Pustijanac, E.; Jukic, M.; Skrlec, I. Homeostasis and Dysbiosis of the Intestinal Microbiota: Comparing Hallmarks of a Healthy State with Changes in Inflammatory Bowel Disease. Microorganisms 2022, 10, 2405.
  4. Png, C.W.; Lindén, S.K.; Gilshenan, K.S.; Zoetendal, E.G.; McSweeney, C.S.; Sly, L.I.; McGuckin, M.A.; Florin, T.H. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am. J. Gastroenterol. 2010, 105, 2420–2428.
  5. Wehkamp, J.; Salzman, N.H.; Porter, E.; Nuding, S.; Weichenthal, M.; Petras, R.E.; Shen, B.; Schaeffeler, E.; Schwab, M.; Linzmeier, R.; et al. Reduced Paneth cell α-defensins in ileal Crohn’s disease. Proc. Natl. Acad. Sci. USA 2005, 102, 18129–18134.
  6. Manos, J. The human microbiome in disease and pathology. APMIS 2022, 130, 690–705.
  7. Lal, S.; Kandiyal, B.; Ahuja, V.; Takeda, K.; Das, B. Gut microbiome dysbiosis in inflammatory bowel disease. Prog. Mol. Biol. Transl. Sci. 2022, 192, 179–204.
  8. Lee, M.; Chang, E.B. Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues. Gastroenterology 2021, 160, 524–537.
  9. Ağagündüz, D.; Cocozza, E.; Cemali, Ö.; Bayazıt, A.D.; Nanì, M.F.; Cerqua, I.; Morgillo, F.; Saygılı, S.K.; Berni Canani, R.; Amero, P.; et al. Understanding the role of the gut microbiome in gastrointestinal cancer: A review. Front. Pharmacol. 2023, 14, 1130562.
  10. Simon, D.; Kellermayer, R. Disturbed Pediatric Gut Microbiome Maturation in the Developmental Origins of Subsequent Chronic Disease. J. Pediatr. Gastroenterol. Nutr. 2023, 76, 123–127.
  11. de Vos, W.M.; Tilg, H.; Van Hul, M.; Cani, P.D. Gut microbiome and health: Mechanistic insights. Gut 2022, 71, 1020–1032.
  12. Morgan, X.C.; Tickle, T.L.; Sokol, H.; Gevers, D.; Devaney, K.L.; Ward, D.V.; Reyes, J.A.; Shah, S.A.; LeLeiko, N.; Snapper, S.B.; et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012, 13, R79.
  13. Azimi, T.; Nasiri, M.J.; Chirani, A.S.; Pouriran, R.; Dabiri, H. The role of bacteria in the inflammatory bowel disease development: A narrative review. APMIS 2018, 126, 275–283.
  14. Gomaa, E.Z. Human gut microbiota/microbiome in health and diseases: A review. Antonie Van Leeuwenhoek 2020, 113, 2019–2040.
  15. Smits, W.K.; Lyras, D.; Lacy, D.B.; Wilcox, M.H.; Kuijper, E.J. Clostridium difficile infection. Nat. Rev. Dis. Primers 2016, 2, 16020.
  16. Wu, S.; Rhee, K.J.; Albesiano, E.; Rabizadeh, S.; Wu, X.; Yen, H.R.; Huso, D.L.; Brancati, F.L.; Wick, E.; McAllister, F.; et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 2009, 15, 1016–1022.
  17. Goodwin, A.C.; Destefano Shields, C.E.; Wu, S.; Huso, D.L.; Wu, X.; Murray-Stewart, T.R.; Hacker-Prietz, A.; Rabizadeh, S.; Woster, P.M.; Sears, C.L.; et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl. Acad. Sci. USA 2011, 108, 15354–15359.
  18. Aviles-Jimenez, F.; Vazquez-Jimenez, F.; Medrano-Guzman, R.; Mantilla, A.; Torres, J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci. Rep. 2014, 4, 4202.
  19. Seishima, J.; Iida, N.; Kitamura, K.; Yutani, M.; Wang, Z.; Seki, A.; Yamashita, T.; Sakai, Y.; Honda, M.; Yamashita, T.; et al. Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome Biol. 2019, 20, 252.
  20. Zhang, J.; Hoedt, E.C.; Liu, Q.; Berendsen, E.; Teh, J.J.; Hamilton, A.; AW, O.B.; Ching, J.Y.L.; Wei, H.; Yang, K.; et al. Elucidation of Proteus mirabilis as a Key Bacterium in Crohn’s Disease Inflammation. Gastroenterology 2021, 160, 317–330.e11.
  21. Wei, S.; Bahl, M.I.; Baunwall, S.M.D.; Hvas, C.L.; Licht, T.R. Determining Gut Microbial Dysbiosis: A Review of Applied Indexes for Assessment of Intestinal Microbiota Imbalances. Appl. Environ. Microbiol. 2021, 87, e00395-21.
  22. Gevers, D.; Kugathasan, S.; Denson, L.A.; Vazquez-Baeza, Y.; Van Treuren, W.; Ren, B.; Schwager, E.; Knights, D.; Song, S.J.; Yassour, M.; et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 2014, 15, 382–392.
  23. Shaw, K.A.; Bertha, M.; Hofmekler, T.; Chopra, P.; Vatanen, T.; Srivatsa, A.; Prince, J.; Kumar, A.; Sauer, C.; Zwick, M.E.; et al. Dysbiosis, inflammation, and response to treatment: A longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. Genome Med. 2016, 8, 75.
  24. Kho, Z.Y.; Lal, S.K. The Human Gut Microbiome—A Potential Controller of Wellness and Disease. Front. Microbiol. 2018, 9, 1835.
  25. Nagao-Kitamoto, H.; Shreiner, A.B.; Gillilland, M.G., 3rd; Kitamoto, S.; Ishii, C.; Hirayama, A.; Kuffa, P.; El-Zaatari, M.; Grasberger, H.; Seekatz, A.M.; et al. Functional Characterization of Inflammatory Bowel Disease-Associated Gut Dysbiosis in Gnotobiotic Mice. Cell. Mol. Gastroenterol. Hepatol. 2016, 2, 468–481.
  26. Mark-Christensen, A.; Lange, A.; Erichsen, R.; Froslev, T.; Esen, B.O.; Sorensen, H.T.; Kappelman, M.D. Early-Life Exposure to Antibiotics and Risk for Crohn’s Disease: A Nationwide Danish Birth Cohort Study. Inflamm. Bowel Dis. 2022, 28, 415–422.
  27. Fitzgerald, R.S.; Sanderson, I.R.; Claesson, M.J. Paediatric Inflammatory Bowel Disease and its Relationship with the Microbiome. Microb. Ecol. 2021, 82, 833–844.
  28. Zhuang, X.; Liu, C.; Zhan, S.; Tian, Z.; Li, N.; Mao, R.; Zeng, Z.; Chen, M. Gut Microbiota Profile in Pediatric Patients with Inflammatory Bowel Disease: A Systematic Review. Front. Pediatr. 2021, 9, 626232.
  29. Hoyhtya, M.; Korpela, K.; Saqib, S.; Junkkari, S.; Nissila, E.; Nikkonen, A.; Dikareva, E.; Salonen, A.; de Vos, W.M.; Kolho, K.L. Quantitative Fecal Microbiota Profiles Relate to Therapy Response during Induction with Tumor Necrosis Factor alpha Antagonist Infliximab in Pediatric Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2023, 29, 116–124.
  30. Kugathasan, S.; Denson, L.A.; Walters, T.D.; Kim, M.O.; Marigorta, U.M.; Schirmer, M.; Mondal, K.; Liu, C.; Griffiths, A.; Noe, J.D.; et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: A multicentre inception cohort study. Lancet 2017, 389, 1710–1718.
  31. Kansal, S.; Catto-Smith, A.G.; Boniface, K.; Thomas, S.; Cameron, D.J.; Oliver, M.; Alex, G.; Kirkwood, C.D.; Wagner, J. The Microbiome in Paediatric Crohn’s Disease-A Longitudinal, Prospective, Single-Centre Study. J. Crohn’s Colitis 2019, 13, 1044–1054.
  32. Ihekweazu, F.D.; Versalovic, J. Development of the Pediatric Gut Microbiome: Impact on Health and Disease. Am. J. Med. Sci. 2018, 356, 413–423.
  33. Bolte, L.A.; Vich Vila, A.; Imhann, F.; Collij, V.; Gacesa, R.; Peters, V.; Wijmenga, C.; Kurilshikov, A.; Campmans-Kuijpers, M.J.E.; Fu, J.; et al. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome. Gut 2021, 70, 1287–1298.
  34. Yan, J.; Wang, L.; Gu, Y.; Hou, H.; Liu, T.; Ding, Y.; Cao, H. Dietary Patterns and Gut Microbiota Changes in Inflammatory Bowel Disease: Current Insights and Future Challenges. Nutrients 2022, 14, 4003.
  35. Zheng, J.; Hoffman, K.L.; Chen, J.S.; Shivappa, N.; Sood, A.; Browman, G.J.; Dirba, D.D.; Hanash, S.; Wei, P.; Hebert, J.R.; et al. Dietary inflammatory potential in relation to the gut microbiome: Results from a cross-sectional study. Br. J. Nutr. 2020, 124, 931–942.
  36. Peters, V.; Tigchelaar-Feenstra, E.F.; Imhann, F.; Dekens, J.A.M.; Swertz, M.A.; Franke, L.H.; Wijmenga, C.; Weersma, R.K.; Alizadeh, B.Z.; Dijkstra, G.; et al. Habitual dietary intake of IBD patients differs from population controls: A case-control study. Eur. J. Nutr. 2021, 60, 345–356.
  37. Racine, A.; Carbonnel, F.; Chan, S.S.; Hart, A.R.; Bueno-de-Mesquita, H.B.; Oldenburg, B.; van Schaik, F.D.; Tjonneland, A.; Olsen, A.; Dahm, C.C.; et al. Dietary Patterns and Risk of Inflammatory Bowel Disease in Europe: Results from the EPIC Study. Inflamm. Bowel Dis. 2016, 22, 345–354.
  38. Rinninella, E.; Raoul, P.; Cintoni, M.; Franceschi, F.; Miggiano, G.A.D.; Gasbarrini, A.; Mele, M.C. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms 2019, 7, 14.
  39. Vandenplas, Y.; Carnielli, V.P.; Ksiazyk, J.; Luna, M.S.; Migacheva, N.; Mosselmans, J.M.; Picaud, J.C.; Possner, M.; Singhal, A.; Wabitsch, M. Factors affecting early-life intestinal microbiota development. Nutrition 2020, 78, 110812.
  40. Hviid, A.; Svanstrom, H.; Frisch, M. Antibiotic use and inflammatory bowel diseases in childhood. Gut 2011, 60, 49–54.
  41. Örtqvist, A.K.; Lundholm, C.; Halfvarson, J.; Ludvigsson, J.F.; Almqvist, C. Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: A population-based study. Gut 2019, 68, 218–225.
  42. Mazzola, G.; Murphy, K.; Ross, R.P.; Di Gioia, D.; Biavati, B.; Corvaglia, L.T.; Faldella, G.; Stanton, C. Early Gut Microbiota Perturbations Following Intrapartum Antibiotic Prophylaxis to Prevent Group B Streptococcal Disease. PLoS ONE 2016, 11, e0157527.
  43. Nogacka, A.; Salazar, N.; Suárez, M.; Milani, C.; Arboleya, S.; Solís, G.; Fernández, N.; Alaez, L.; Hernández-Barranco, A.M.; de Los Reyes-Gavilán, C.G.; et al. Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates. Microbiome 2017, 5, 93.
  44. Horta, B.L.; Loret de Mola, C.; Victora, C.G. Breastfeeding and intelligence: A systematic review and meta-analysis. Acta Paediatr. 2015, 104, 14–19.
  45. Keag, O.E.; Norman, J.E.; Stock, S.J. Long-term risks and benefits associated with cesarean delivery for mother, baby, and subsequent pregnancies: Systematic review and meta-analysis. PLoS Med. 2018, 15, e1002494.
  46. Dogaru, C.M.; Nyffenegger, D.; Pescatore, A.M.; Spycher, B.D.; Kuehni, C.E. Breastfeeding and childhood asthma: Systematic review and meta-analysis. Am. J. Epidemiol. 2014, 179, 1153–1167.
  47. Xu, L.; Lochhead, P.; Ko, Y.; Claggett, B.; Leong, R.W.; Ananthakrishnan, A.N. Systematic review with meta-analysis: Breastfeeding and the risk of Crohn’s disease and ulcerative colitis. Aliment. Pharmacol. Ther. 2017, 46, 780–789.
  48. Riva, A.; Borgo, F.; Lassandro, C.; Verduci, E.; Morace, G.; Borghi, E.; Berry, D. Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations. Environ. Microbiol. 2017, 19, 95–105.
  49. Ahmadizar, F.; Vijverberg, S.J.H.; Arets, H.G.M.; de Boer, A.; Lang, J.E.; Garssen, J.; Kraneveld, A.; Maitland-van der Zee, A.H. Early-life antibiotic exposure increases the risk of developing allergic symptoms later in life: A meta-analysis. Allergy 2018, 73, 971–986.
  50. Piovani, D.; Danese, S.; Peyrin-Biroulet, L.; Nikolopoulos, G.K.; Lytras, T.; Bonovas, S. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology 2019, 157, 647–659.e4.
  51. Pittayanon, R.; Lau, J.T.; Leontiadis, G.I.; Tse, F.; Yuan, Y.; Surette, M.; Moayyedi, P. Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review. Gastroenterology 2020, 158, 930–946.e1.
  52. Amos, G.C.A.; Sergaki, C.; Logan, A.; Iriarte, R.; Bannaga, A.; Chandrapalan, S.; Wellington, E.M.H.; Rijpkema, S.; Arasaradnam, R.P. Exploring how microbiome signatures change across inflammatory bowel disease conditions and disease locations. Sci. Rep. 2021, 11, 18699.
  53. Lloyd-Price, J.; Arze, C.; Ananthakrishnan, A.N.; Schirmer, M.; Avila-Pacheco, J.; Poon, T.W.; Andrews, E.; Ajami, N.J.; Bonham, K.S.; Brislawn, C.J.; et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 2019, 569, 655–662.
  54. Gallagher, K.; Catesson, A.; Griffin, J.L.; Holmes, E.; Williams, H.R.T. Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review. J. Crohn’s Colitis 2021, 15, 813–826.
  55. Serrano-Gomez, G.; Mayorga, L.; Oyarzun, I.; Roca, J.; Borruel, N.; Casellas, F.; Varela, E.; Pozuelo, M.; Machiels, K.; Guarner, F.; et al. Dysbiosis and relapse-related microbiome in inflammatory bowel disease: A shotgun metagenomic approach. Comput. Struct. Biotechnol. J. 2021, 19, 6481–6489.
  56. Pascal, V.; Pozuelo, M.; Borruel, N.; Casellas, F.; Campos, D.; Santiago, A.; Martinez, X.; Varela, E.; Sarrabayrouse, G.; Machiels, K.; et al. A microbial signature for Crohn’s disease. Gut 2017, 66, 813–822.
  57. Alam, M.T.; Amos, G.C.A.; Murphy, A.R.J.; Murch, S.; Wellington, E.M.H.; Arasaradnam, R.P. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog. 2020, 12, 1.
  58. Gronbach, K.; Flade, I.; Holst, O.; Lindner, B.; Ruscheweyh, H.J.; Wittmann, A.; Menz, S.; Schwiertz, A.; Adam, P.; Stecher, B.; et al. Endotoxicity of Lipopolysaccharide as a Determinant of T-Cell−Mediated Colitis Induction in Mice. Gastroenterology 2014, 146, 765–775.
  59. Petersen, A.M.; Halkjær, S.I.; Gluud, L.L. Intestinal colonization with phylogenetic group B2 Escherichia coli related to inflammatory bowel disease: A systematic review and meta-analysis. Scand. J. Gastroenterol. 2015, 50, 1199–1207.
  60. Yatsunenko, T.; Rey, F.E.; Manary, M.J.; Trehan, I.; Dominguez-Bello, M.G.; Contreras, M.; Magris, M.; Hidalgo, G.; Baldassano, R.N.; Anokhin, A.P.; et al. Human gut microbiome viewed across age and geography. Nature 2012, 486, 222–227.
  61. Hollister, E.B.; Riehle, K.; Luna, R.A.; Weidler, E.M.; Rubio-Gonzales, M.; Mistretta, T.A.; Raza, S.; Doddapaneni, H.V.; Metcalf, G.A.; Muzny, D.M.; et al. Structure and function of the healthy pre-adolescent pediatric gut microbiome. Microbiome 2015, 3, 36.
  62. Olbjørn, C.; Cvancarova Småstuen, M.; Thiis-Evensen, E.; Nakstad, B.; Vatn, M.H.; Jahnsen, J.; Ricanek, P.; Vatn, S.; Moen, A.E.F.; Tannæs, T.M.; et al. Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease—Associations with disease phenotype, treatment, and outcome. Clin. Exp. Gastroenterol. 2019, 12, 37–49.
  63. Kowalska-Duplaga, K.; Gosiewski, T.; Kapusta, P.; Sroka-Oleksiak, A.; Wedrychowicz, A.; Pieczarkowski, S.; Ludwig-Slomczynska, A.H.; Wolkow, P.P.; Fyderek, K. Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease. Sci. Rep. 2019, 9, 18880.
  64. de Meij, T.G.J.; de Groot, E.F.J.; Peeters, C.F.W.; de Boer, N.K.H.; Kneepkens, C.M.F.; Eck, A.; Benninga, M.A.; Savelkoul, P.H.M.; van Bodegraven, A.A.; Budding, A.E. Variability of core microbiota in newly diagnosed treatment-naive paediatric inflammatory bowel disease patients. PLoS ONE 2018, 13, e0197649.
  65. Kolho, K.L.; Korpela, K.; Jaakkola, T.; Pichai, M.V.; Zoetendal, E.G.; Salonen, A.; de Vos, W.M. Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation. Am. J. Gastroenterol. 2015, 110, 921–930.
  66. Malham, M.; Lilje, B.; Houen, G.; Winther, K.; Andersen, P.S.; Jakobsen, C. The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease. Scand. J. Gastroenterol. 2019, 54, 969–975.
  67. Wang, Y.; Gao, X.; Zhang, X.; Xiao, F.; Hu, H.; Li, X.; Dong, F.; Sun, M.; Xiao, Y.; Ge, T.; et al. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease. Gut Microbes 2021, 13, 1865708.
  68. Elmaghrawy, K.; Fleming, P.; Fitzgerald, K.; Cooper, S.; Dominik, A.; Hussey, S.; Moran, G.P. The Oral Microbiome in Treatment-Naïve Paediatric IBD Patients Exhibits Dysbiosis Related to Disease Severity that Resolves following Therapy. J. Crohn’s Colitis 2022, 17, 553–564.
  69. Bliven, K.A.; Maurelli, A.T. Evolution of Bacterial Pathogens Within the Human Host. Microbiol. Spectr. 2016, 4, 10–1128.
  70. Venkatakrishnan, A.; Holzknecht, Z.E.; Holzknecht, R.; Bowles, D.E.; Kotzé, S.H.; Modliszewski, J.L.; Parker, W. Evolution of bacteria in the human gut in response to changing environments: An invisible player in the game of health. Comput. Struct. Biotechnol. J. 2021, 19, 752–758.
  71. Wong, E.; Lui, K.; Day, A.S.; Leach, S.T. Manipulating the neonatal gut microbiome: Current understanding and future perspectives. Arch. Dis. Child. Fetal Neonatal Ed. 2022, 107, 346–350.
  72. Mueller, N.T.; Bakacs, E.; Combellick, J.; Grigoryan, Z.; Dominguez-Bello, M.G. The infant microbiome development: Mom matters. Trends Mol. Med. 2015, 21, 109–117.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pediatrics
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Pui Yin Wong
,
Carmen Yip
,
Daniel A. Lemberg
,
Andrew S. Day
,
Steven T. Leach
View Times: 200
Revisions: 2 times (View History)
Update Date: 04 Dec 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback